Roche writes off $3B+ in pipeline as­sets, $750M for Spark-ac­quired gene ther­a­pies

Roche faces a down­ward turn in rev­enue this year, writ­ing down or off bil­lions in as­sets, and pre­dict­ing a de­cline in rev­enue from Covid-19 prod­ucts as seen in­dus­try­wide.

Roche put out word Thurs­day morn­ing in its fi­nan­cial re­port, de­tail­ing bil­lions of dol­lars that the com­pa­ny has writ­ten off, which equaled more than $700 mil­lion in 2021 and more than $3.1 bil­lion in 2022.

An im­pair­ment charge is an ac­count­ing term used to par­tial­ly or ful­ly write off the val­ue of an as­set de­pend­ing on mar­ket fac­tors or oth­er con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER